Antibody Drug Conjugates Market to surpass USD 26.5 billion by 2032, says Global Market Insights Inc.
June 20, 2023 20:00 ET
|
Global Market Insights Inc.
Selbyville, Delaware, June 20, 2023 (GLOBE NEWSWIRE) -- Antibody Drug Conjugates Market size will cross USD 26.5 billion by 2032. Growing advancements in antibody engineering and conjugation...
Thermosome Receives Regulatory Approval for First-In-Human Trial with its Lead Program THE001
March 28, 2023 03:45 ET
|
AKAMPION
- Novel compound for targeted tumor therapy to be evaluated in patients with soft tissue sarcoma- First patients to be enrolled in Q2, 2023 Munich, Germany – March 28, 2023 – Thermosome, a...
Cybrexa Therapeutics Completes Successful Pre-IND Meeting With FDA for CBX-12 (alphalex™-exatecan), a Novel Treatment for Solid Tumors
July 07, 2020 07:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., July 07, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Cybrexa Therapeutics to Present First Efficacy and Safety Data From Its Lead Program CBX-12 and Initial Data From CBX-13 at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
May 15, 2020 04:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., May 15, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Cybrexa Therapeutics to Present at BIO Digital and Sachs 6th Annual Digital Immuno-Oncology Innovation Forum
May 07, 2020 11:27 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., May 07, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Cybrexa Therapeutics Announces CBX-12 as Lead Development Program
January 09, 2020 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...